Baker Bros. Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Baker Bros. Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-147,996	Closed	-$710K	–	133
2021 Q1	$710K	Hold	147,996	–	–	﹤0.01%	122
2020 Q4	$641K	Sell	147,996 -15,834	-10%	-$67.8K	﹤0.01%	122
2020 Q3	$675K	Sell	163,830 -8,800	-5%	-$34K	﹤0.01%	116
2020 Q2	$442K	Hold	172,630	–	–	﹤0.01%	111
2020 Q1	$499K	Hold	172,630	–	–	﹤0.01%	104
2019 Q4	$654K	Hold	172,630	–	–	﹤0.01%	95
2019 Q3	$883K	Hold	172,630	–	–	0.01%	99
2019 Q2	$1.07M	Hold	172,630	–	–	0.01%	94
2019 Q1	$1.23M	Hold	172,630	–	–	0.01%	87
2018 Q4	$1.47M	Hold	172,630	–	–	0.01%	78
2018 Q3	$3.46M	Hold	172,630	–	–	0.02%	80
2018 Q2	$4.46M	Hold	172,630	–	–	0.03%	81
2018 Q1	$4.13M	Hold	172,630	–	–	0.04%	82
2017 Q4	$5.85M	Hold	172,630	–	–	0.05%	73
2017 Q3	$3.65M	Hold	172,630	–	–	0.03%	84
2017 Q2	$3.02M	Hold	172,630	–	–	0.03%	74
2017 Q1	$3.02M	Hold	172,630	–	–	0.02%	78
2016 Q4	$2.92M	Hold	172,630	–	–	0.03%	79
2016 Q3	$2.83M	Hold	172,630	–	–	0.03%	82
2016 Q2	$2.61M	Hold	172,630	–	–	0.03%	87
2016 Q1	$2.5M	Buy	+172,630	New	+$2.91M	0.03%	92

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baker Bros. Advisors's ADMS Position: Q2 2021 in Review

Baker Bros. Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 147,996 shares — an estimated $710K sold.

Baker Bros. Advisors first reported a position in ADMS in Q1 2016 and held it in 21 quarters. The position peaked at $5.85M in Q4 2017. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

Baker Bros. Advisors reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Baker Bros. Advisors sold 147,996 Adamas Pharmaceuticals shares in Q2 2021, an estimated $710K.
Baker Bros. Advisors first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 21 quarters.
Baker Bros. Advisors's Adamas Pharmaceuticals position peaked at $5.85M in Q4 2017.
67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.